BioForce Receives Notice of Allowance for Its 'Chip-On-A-Tip' Patent
Posted on: Tuesday, 11 December 2007, 09:01 CST
AMES, Iowa, Dec. 11, 2007 (PRIME NEWSWIRE) -- BioForce Nanosciences Holdings Inc. (OTCBB:BFNH) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for its Chip-On-A-Tip(tm) patent.
Chip-On-A-Tip(tm) (COAT(tm)) is a revolutionary method for performing diagnostic tests on extremely small tissue and liquid samples. It involves placement of an ultra-miniaturized diagnostic test at the end of a device, such as a surgical probe, as a means of collecting the tiny amounts of material necessary for the ultra-miniaturized tests to provide a diagnosis. The COAT method can be applied to the diagnosis of diseases, such as cancer, and for small sample analysis, as is the case with neonates and forensics specimens.
BioForce has utilized COAT to successfully perform cancer protein biomarker screening from as few as four cells, demonstrating the detection of prostate-specific antigen (PSA), which is commonly used for the diagnosis of prostate cancer.
Dr. Eric Henderson, BioForce's CEO, said, "COAT is one example of the NanoDiagnostic testing technologies under development at BioForce. The concept behind NanoDiagnostic tests is to address the many instances where it is highly desirable to be able to obtain a diagnosis using miniscule samples in order to minimize patient invasiveness or simply because larger samples are not readily available. This is particularly important when analyzing protein biomarkers, which are indicators of disease and, unlike DNA, cannot be amplified by any known process. In order to do this, the diagnostic test itself must be of a size scale consistent with the sample size, which can be as small as a single cell. Examples of when this is important include tests involving neonatal blood, forensic specimens, and cells aspirated from a tumor."
Henderson continued, "The Notice of Allowance on the COAT patent is the third significant development in our intellectual property portfolio during 2007. Earlier this year, we received confirmation of our Protein Nanoarray patent, covering protein arrays with feature sizes of less than one micron squared for creating ultra-miniaturized diagnostic tests and micro-environments for the study of cell biology. We also received a Notice of Allowance for our Sindex(tm) chip patent. Sindex chips are indexed silicon substrates that serve as the basis for a host of ultra-miniaturized tests."
Kerry Frey, BioForce's COO, added, "Our platform technology, the Nano eNabler(tm) molecular printing system, is instrumental for the construction of ultra-miniaturized diagnostic tests, such as the COAT device. We believe that COAT is just one of many paradigm-shifting technologies that will emerge from the Nano eNabler's capabilities. Our patented ViriChip(tm) virus detection technology is a second example of products resulting from BioForce's internal use of the Nano eNabler. Additionally, we now have a significant worldwide base of customers who have purchased Nano eNablers and are using them to create an ever-expanding arsenal of forward-looking inventions in areas including health care, tissue engineering, stem cells, neurobiology, cancer cell biology and biosensors."
Frey continued, "As our business grows, we are very cognizant of the importance of continued innovation, both internally and in collaboration with our customer-colleagues. Reaching out to our customers and embracing new ideas and opportunities is a cornerstone of our business philosophy."
About BioForce Nanosciences Holdings, Inc.
BioForce Nanosciences is an innovation company that develops and commercializes nanotechnology-driven tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler(tm) molecular printer, gives the Company and its customers a unique platform for development and discovery in areas such as cell biology, biosensors, and ultra-miniaturized surface modification. For more information, visit www.bioforcenano.com or call 515-233-8333.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.
This news release was distributed by PrimeNewswire, www.primenewswire.com
CONTACT: BioForce Nanosciences Holdings, Inc. Greg Brown, CFO 515-233-8333 ext. 118 gbrown@bioforcenano.com RedChip Companies, Inc. Investor Relations Dave Gentry 1-800-REDCHIP (733-2447) ext. 104 dave@redchip.com www.redchip.com
Source: PrimeNewswire
Related Articles
- livethesource(TM) Launches With the World's First and Only Patented, Fully Nano-Encapsulated Liquid Vitamin, Mineral and Herbal Supplement
- Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
- Corgenix AspirinWorks(R) Test Now Offered Through Quest Diagnostics
- Sequenom and SensiGen Enter into Alliance to Develop and Commercialize Ultra-Sensitive Human Papillomavirus (HPV) Test and Other Advanced Proprietary Diagnostics
- New Blood ''Signature'' Test Holds Key to Successful Early Alzheimer's Diagnosis and Treatment
- Advanced Battery Technologies, Inc.'s Wholly Owned Subsidiary Issued China Patent for Nano Material Lithium Ion Battery
- Epigenomics AG: PITX2 Prostate Cancer Molecular Classification Test Successfully Transferred to Affymetrix Diagnostic Platform
- Agendia's MammaPrint(R) Micro-Array Test Confirmed to Be a Reliable Diagnostic Tool for Breast Cancer
- BioTech Medics, Inc. Announces Avian Bird Flue Virus Test Results With the Patented SHBAN(TM) Disinfectant
- BioMag Corporation Acquires Biospectrum Technologies, Inc., A Biomedical Company That Designs and Patents Diagnostic Equipment and Immunoassays
 |
 |
User Comments (0)
RSS Feeds